Hauber argues that investors are expecting Astra to imitate the strategy of Bristol-Myers Squibb, which is growing by doing small acquisitions of promising drugs.

FORBES: Analyst Says To Sell AstraZeneca Because It Might Raise R&D Spending

Morgan European pharmaceuticals analyst Alexandra Hauber advised investors to sell AstraZeneca shares, downgrading the stock from Neutral to Underweight, because she argues the company is likely to have raise the amount that is spends on both marketing and research and development.

FORBES: Analyst Says To Sell AstraZeneca Because It Might Raise R&D Spending